Spark Shadows BioMarin In Hemophilia Gene Therapy Race

Spark Therapeutics, the company likely to launch the first gene therapy in the U.S., is presenting data on both of its gene therapies for hemophilia this morning at the annual meeting of the American Society of Hematology in Atlanta.

Source: Forbes.com Healthcare News - December 11, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:ONCE NASDAQ:BMRN Source Type: news